accountAB Sanitas for the equivalent of just over $500-million, including debt. The company is a generic manufacturer in Eastern Europe, which fits directly into Valeants role as a leading player in Central and Eastern Europe. The acquisition is very similar to...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Valeant casts brusied egos aside, buys again
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account